Term ends Apr 17, 2039 · High confidence
20-year base term ends Apr 17, 2039
Held by Tempest Therapeutics, Inc.
Filed Jun 23, 2022 as application 17/847,811 · Granted Oct 24, 2023
Base term, 20 years from filing
Today
2019
2039
Clock starts
Apr 17, 2019
Apr 17, 2019
Term ends
Apr 17, 2039
Apr 17, 2039
Granted
Oct 24, 2023
Oct 24, 2023
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,968,201, US 11,472,789, to Apr 17, 2039. The term already ends on or before that date, so the cap shortened nothing.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 17, 2019, when application 16/387,294, the earliest non-provisional in its chain, was filed (this one was filed Jun 23, 2022) | Apr 17, 2039 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,968,201, US 11,472,789) | resolves to Apr 17, 2039, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 17, 2039 | High confidence |
This family
| US 10,968,201 | In force Apr 2039 | Apr 2039 |
| US 11,472,789 | In force Apr 2039 | Apr 2039 |
| US 11,795,156 | this patent Apr 2039 | Apr 2039 |
| US 12,215,093 | In force Apr 2039 | Apr 2039 |
| Application 18/988,376 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 20, 2022 Reel 60566, frame 101 | Bravo, Yalda; Chen, Austin Chih-yu; Nagamizo, Joe Fred | Inception Sciences, Inc. | Assignment of Assignor's Interest |
| Jul 20, 2022 Reel 60566, frame 457 | Inception Sciences, Inc.; Inception Sciences Canada, Inc. | Tempest Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jul 20, 2022 Reel 60768, frame 91 | Ding, Jinyue; Gomez, Robert; Lam, Heather; Oballa, Renata Marcella; Powell, David Andrew; Sheng, Tao | Inception Sciences Canada, Inc. | Assignment of Assignor's Interest |
| Dec 28, 2022 Reel 62221, frame 808 | Tempesttx, Inc. (F/K/A Tempest Therapeutics, Inc.); Tempest Therapeutics, Inc. (F/K/A Millendo Therapeutics, Inc.); Millendo Therapeutics US, Inc. | Oxford Finance LLC | Security Interest |
| Apr 10, 2025 Reel 70806, frame 566 | Oxford Finance LLC | Tempesttx, Inc.; Tempest Therapeutics, Inc.; Millendo Therapeutics US, Inc. | Release of Security Interest |
| Apr 10, 2025 reel/frame not recorded | Oxford Finance LLC | Tempesttx, Inc. | Release of Security Interest |
| Apr 10, 2025 reel/frame not recorded | Oxford Finance LLC | Tempest Therapeutics, Inc. | Release of Security Interest |
| Apr 10, 2025 reel/frame not recorded | Oxford Finance LLC | Millendo Therapeutics US, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2039
Term ends Apr 17, 2039. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,968,201, US 11,472,789, ends no earlier than this term, so it caps nothing.
Citations
2
later US patents cite this one
That is above the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.